Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?

Affiliations

¹ Indiana University Simon Cancer Center, Indianapolis, IN.
² University of California, San Francisco, San Francisco, CA alan.venook@ucsf.edu.

Editorial

Bert H O'Neil et al. J Clin Oncol. 2015.

. 2015 Nov 10;33(32):3686-8.

doi: 10.1200/JCO.2015.62.8495. Epub 2015 Aug 31.

¹ Indiana University Simon Cancer Center, Indianapolis, IN.
² University of California, San Francisco, San Francisco, CA alan.venook@ucsf.edu.

No abstract available

Comment on

Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Möhler M, Jung A, Kirchner T, Heinemann V. Modest DP, et al. J Clin Oncol. 2015 Nov 10;33(32):3718-26. doi: 10.1200/JCO.2015.61.2887. Epub 2015 Aug 10. J Clin Oncol. 2015. PMID: 26261259 Clinical Trial.